Roche, Chugai Pharma to transfer Bonviva business in Japan to Taisho Pharma

Published On 2022-11-26 07:21 GMT   |   Update On 2022-11-26 07:21 GMT
Advertisement

Tokyo: Chugai Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. have announced that Chugai, Taisho, and F. Hoffmann-La Roche Ltd (hereafter, Roche) have entered into an agreement to transfer the business in Japan concerning the ibandronate sodium hydrate injection [brand name: Bonviva Injection 1 mg Syringe] and the oral formulation [brand name: Bonviva Tablet 100 mg] (collectively "Bonviva"), from Roche and Chugai to Taisho. The closing of the transaction is expected to take place after certain conditions including approvals from relevant authorities are fulfilled. Chugai in-licensed Bonviva from Roche and is the marketing authorization holder in Japan.

Read also: Roche, Jnana Therapeutics collaborate for discovery of small molecule drugs for cancer

Chugai and Taisho concluded an agreement in 2006 to co-develop and co-market Bonviva in Japan. After conducting clinical studies in Japan, the two companies have been jointly marketing Bonviva since the launch of the injection in 2013. In consideration of the maturity of the product lifecycle, Chugai, Taisho, and Roche revisited the marketing of Bonviva in Japan and concluded that Taisho should solely market Bonviva after transferring assets related to Bonviva that are owned by Roche and Chugai, including the marketing authorization and intellectual property rights (patents and trademarks, etc.), to Taisho.

Read also: Roche gets USFDA nod for VENTANA FOLR1 RxDx Assay to detect ovarian cancer patients eligible for ELAHERE

Following the signing of the asset purchase agreement, Taisho and Chugai will proceed with the necessary administrative and legal procedures for the completion of the transaction. The transfer of the marketing authorization is scheduled to take place on April 3, 2023. Taisho will be solely responsible for the marketing of and information provision activities for Bonviva in Japan thereafter.

Read also: Chugai Pharma Herceptin gets Japanese nod for additional indication of salivary gland cancer

Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News